JP6889116B2 - 安定トリエンチン製剤 - Google Patents
安定トリエンチン製剤 Download PDFInfo
- Publication number
- JP6889116B2 JP6889116B2 JP2017559292A JP2017559292A JP6889116B2 JP 6889116 B2 JP6889116 B2 JP 6889116B2 JP 2017559292 A JP2017559292 A JP 2017559292A JP 2017559292 A JP2017559292 A JP 2017559292A JP 6889116 B2 JP6889116 B2 JP 6889116B2
- Authority
- JP
- Japan
- Prior art keywords
- trientine
- packaged pharmaceutical
- pharmaceutical preparation
- preparation according
- packaged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 title claims description 46
- 229960001124 trientine Drugs 0.000 title claims description 43
- 238000002360 preparation method Methods 0.000 title description 2
- 238000004806 packaging method and process Methods 0.000 claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 229910052802 copper Inorganic materials 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 5
- 208000018839 Wilson disease Diseases 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 5
- -1 dihydrochloride Chemical compound 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 238000000354 decomposition reaction Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 3
- 239000002274 desiccant Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 238000011287 therapeutic dose Methods 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 2
- 239000011888 foil Substances 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 229940070765 laurate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000005487 naphthalate group Chemical class 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 239000011101 paper laminate Substances 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 2
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 2
- 229920006254 polymer film Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical class [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 229920000768 polyamine Polymers 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WYHIICXRPHEJKI-UHFFFAOYSA-N Trientine hydrochloride Chemical compound Cl.Cl.NCCNCCNCCN WYHIICXRPHEJKI-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960002408 trientine hydrochloride Drugs 0.000 description 2
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940036222 syprine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本出願は、2015年2月3日出願の米国仮特許出願番号第62/111,522号の優先権を主張し、その開示は、本明細書によりそのまま全体が参照として援用される。
本発明は、疾患治療用の、1種または複数の治療用のアミンもしくはポリアミン銅キレート剤、例えば、トリエンチン及びトリエンチン塩を含有する医薬剤形に関する。本発明はまた、ポリアミン銅キレート剤を安定化する組成物及び方法に関する。本発明は、製剤の最終的な製造時点から患者により使用されるまでの期間、活性成分の実質的な分解を示さない、トリエンチンまたはその塩の安定医薬製剤を提供する。
Claims (19)
- トリエンチンまたはトリエンチンの薬学上許容される塩を含有する、カプセル又は錠剤の固体経口製剤を、密封した包装中に含み、当該密封した包装が、不活性雰囲気中に密封された単回使用量のトリエンチンカプセル又は錠剤を含む、包装された医薬製剤。
- 前記不活性雰囲気は、窒素である、請求項1に記載の包装された医薬製剤。
- 前記トリエンチンの分解は、周辺温度(すなわち室温)(20〜25℃)であっても実質的に阻止される、請求項1又は2のいずれか1項に記載の包装された医薬製剤。
- トリエンチンは、遊離塩基形をしている、請求項3に記載の包装された医薬製剤。
- トリエンチンは、トリエンチンの塩酸塩、二塩酸塩、臭化水素酸塩、硫酸塩、重硫酸塩、リン酸塩、硝酸塩、酢酸塩、ステアリン酸塩、ラウリン酸塩、安息香酸塩、乳酸塩、リン酸塩、トシル酸塩、クエン酸塩、マレイン酸塩、フマル酸塩、コハク酸塩、酒石酸塩、ナフチル酸塩、またはメシル酸塩の形をしている、請求項3に記載の包装された医薬製剤。
- トリエンチンは、トリエンチンの塩酸塩または二塩酸塩の形をしている、請求項3に記載の包装された医薬製剤。
- さらに、トリエンチンではないアミン系キレート剤またはトリエンチンの薬学上許容される塩、酸素消去剤、または乾燥剤を含む、請求項3に記載の包装された医薬製剤。
- 前記包装がブリスター包装である、請求項3に記載の包装された医薬製剤。
- 前記密封した包装は、アルミニウム、アルミニウム箔積層体、重合体、重合体フィルム積層体、または紙積層体を含む1種または複数の材料から形成される、請求項3に記載の包装された医薬製剤。
- 前記密封した包装は、PET、ポリエチレン、及びポリプロピレンからなる群より選択される重合体から形成される、請求項3に記載の包装された医薬製剤。
- 前記密封した包装は、単回治療用量のトリエンチンを含有する、請求項3に記載の包装された医薬製剤。
- 前記トリエンチンは、前記ブリスター包装内に配置された錠剤またはカプセル剤中に存在する、請求項8に記載の包装された医薬製剤。
- トリエンチン250mgを含む、請求項8に記載の包装された医薬製剤。
- 酸素及び湿気を排除した不活性雰囲気下、トリエンチンを包装することを含む、請求項3に記載の包装された医薬製剤の、作製方法。
- 前記不活性雰囲気は、窒素である、請求項14に記載の方法。
- 過剰な銅が身体から除去されない疾患または症状の治療が必要な患者において当該疾患又は症状を治療するための、請求項3に記載の包装された医薬製剤。
- 前記患者は、ヒトである、請求項16に記載の包装された医薬製剤。
- 前記疾患または症状は、ウィルソン病である、請求項17に記載の包装された医薬製剤。
- 前記医薬製剤は、トリエンチン250mgを含む、請求項18に記載の包装された医薬製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562111522P | 2015-02-03 | 2015-02-03 | |
US62/111,522 | 2015-02-03 | ||
PCT/US2016/016430 WO2016126860A1 (en) | 2015-02-03 | 2016-02-03 | Stable trientine formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018505215A JP2018505215A (ja) | 2018-02-22 |
JP6889116B2 true JP6889116B2 (ja) | 2021-06-18 |
Family
ID=56564661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017559292A Active JP6889116B2 (ja) | 2015-02-03 | 2016-02-03 | 安定トリエンチン製剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10874624B2 (ja) |
EP (1) | EP3265078A1 (ja) |
JP (1) | JP6889116B2 (ja) |
CN (1) | CN107530311A (ja) |
CA (1) | CA3011685C (ja) |
EA (1) | EA201791737A1 (ja) |
WO (1) | WO2016126860A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101851981B1 (ko) * | 2016-11-25 | 2018-04-25 | (주) 에프엔지리서치 | 피부 외피용 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06135825A (ja) * | 1992-10-29 | 1994-05-17 | Mikio Uchida | 医薬製剤及びその製造方法 |
EA008683B1 (ru) | 2002-07-23 | 2007-06-29 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии |
US7513996B2 (en) * | 2002-08-12 | 2009-04-07 | Ge Osmonics, Inc. | Residential reverse osmosis system |
AU2003258909B2 (en) * | 2002-08-20 | 2010-07-08 | Philera New Zealand Limited | Dosage forms and related therapies |
SI21302A (sl) * | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
ES2449066T3 (es) | 2004-07-19 | 2014-03-18 | Philera New Zealand Limited | Síntesis de trietilentetraminas |
BRPI0519561A2 (pt) | 2004-12-27 | 2009-01-27 | King Pharmaceuticals Res & Dev | composiÇço farmacÊutica de hormânio da tireàide, embalagem farmacÊutica, e, mÉtodo de acondicionamento de uma composiÇço farmacÊutica de hormânio da tireàide |
JP2007246092A (ja) | 2006-03-13 | 2007-09-27 | Shionogi & Co Ltd | 包装体 |
KR20100084501A (ko) * | 2007-07-27 | 2010-07-26 | 아톤 파마, 인코포레이티드 | 금속 오염 대응책으로서의 트리엔틴 및 페니실라민의 용도 |
UY33469A (es) | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
WO2014140097A1 (en) * | 2013-03-14 | 2014-09-18 | Becton Dickinson France S.A.S. | Packaging system for oxygen-sensitive drugs |
-
2016
- 2016-02-03 CA CA3011685A patent/CA3011685C/en active Active
- 2016-02-03 EA EA201791737A patent/EA201791737A1/ru unknown
- 2016-02-03 US US15/548,345 patent/US10874624B2/en active Active
- 2016-02-03 WO PCT/US2016/016430 patent/WO2016126860A1/en active Application Filing
- 2016-02-03 JP JP2017559292A patent/JP6889116B2/ja active Active
- 2016-02-03 CN CN201680016055.9A patent/CN107530311A/zh active Pending
- 2016-02-03 EP EP16747221.6A patent/EP3265078A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA3011685A1 (en) | 2016-08-11 |
CA3011685C (en) | 2021-07-20 |
JP2018505215A (ja) | 2018-02-22 |
EA201791737A1 (ru) | 2018-03-30 |
WO2016126860A1 (en) | 2016-08-11 |
US20180015053A1 (en) | 2018-01-18 |
EP3265078A1 (en) | 2018-01-10 |
US10874624B2 (en) | 2020-12-29 |
CN107530311A (zh) | 2018-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1615646E (pt) | Formulações farmacêuticas com metilnaltrexona | |
EP2872141A1 (en) | Laquinimod formulations without alkalizing agent | |
BR112014009506B1 (pt) | preparação estabilizada de liberação sustentada contendo eperisona | |
JP6889116B2 (ja) | 安定トリエンチン製剤 | |
CA2466770C (en) | Liquid pharmaceutical formulations of acetaminophen and an alkali metal 1-lactate salt | |
RU2496486C1 (ru) | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение | |
ES2770500T3 (es) | Composición farmacéutica que comprende fingolimod | |
ES2563316T3 (es) | Formas estabilizadas de envasado de sevelamer | |
WO2021250204A1 (en) | Oral formulation comprising a crystalline form of rabeximod | |
TW201008599A (en) | Formulations of canfosfamide and their preparation | |
JP2015503616A (ja) | 強力なhcv阻害薬の安定化医薬製剤 | |
US20230107398A1 (en) | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS | |
ES2467934T3 (es) | Gránulos de prasugrel con estabilidad mejorada | |
WO2016134200A1 (en) | Soft gelatin capsules containing fexofenadine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191029 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200804 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210420 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210520 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6889116 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |